whytestocks
4 years ago
News: $CATS Curt Medeiros, President of OPTUM Advanced Data and Analytics at UnitedHealth Group, Joins Catasys as President and Chief Operating Officer
Catasys, Inc. (NASDAQ: CATS) (“Catasys” or the “Company”), a leading AI and technology-enabled healthcare company, today announced the appointment of Mr. Curt Medeiros as President and Chief Operating Officer. Mr. Terren Peizer, Chairman and CEO of Catasy...
In case you are interested CATS - Curt Medeiros, President of OPTUM Advanced Data and Analytics at UnitedHealth Group, Joins Catasys as President and Chief Operating Officer
ejobkar
5 years ago
$90 million in REVs next year!
"Catasys (CATS) had some pretty interesting guarantees in their loan documents with Goldman Sachs. First off, they have (and this is written in the loan docs) guaranteed that they will do $90 million in revenue in 2020. My guess is that number could very well be where initial guidance for next year comes in, when it’s announced in November. Guidance of $90M will allow CATS to meet the street and have them raise numbers every quarter, which is the Company’s unspoken goal. Eventually, I suspect they come in at around $120M for the year, if not higher.
Secondly, CATS also guaranteed that, in the 12 months for which books had closed, prior to the GS financing, revenue was at least $29M. This means they are on a pace for around $10M in the third quarter, which should mean their target of $35M remains doable. These two guarantees should cause the large short position to reconsider their stance, one would think. But, so far they have yet to blink."
https://tailwindsresearch.com/2019/10/keeping-calm-in-stresa/
Trend-Setter
5 years ago
BioVie (BIVI), one of CATS' Founder, CEO and Chairman Terren Peizer's portfolio of companies is debuting in the Nasdaq Exchange tomorrow!
Will Slattery
Vice President
Listing Qualifications
August 9, 2019
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Division of Corporation Finance:
This is to certify that on August 2, 2019, The Nasdaq Stock Market (the "Exchange") received from BioVie Inc.
(the "Registrant") a copy of the Registrant's application on Form 8-A 12(b) for the registration of the following
securities:
Class A common Stock, par value $.0001 per share
We further certify that the securities described above have been approved by the Exchange for listing and
registration upon official notice of issuance.
We understand that the Registrant is seeking effectiveness of the Form 8-A 12(b) concurrently with
effectiveness of its 1933 Act Registration Statement, and we hereby join in such request.
Sincerely
https://www.sec.gov/Archives/edgar/data/1580149/000135445719000410/8A_Cert_BIVI.pdf
Mr. Terren Peizer dubbed " The Zelig of Wall Street"
>>> BioVie Receives $3.2 Million Equity Investment <<<
On July 3, 2018, BioVie Inc. (OTCQB: BIVI) executed an agreement with Acuitas Group Holdings, LLC (“Acuitas”) and certain other investors to purchase $3.2 million of the Company’s Series A Preferred Stock, which was subsequently converted into approximately 213 million common shares. Acuitas has an option to fund up to an additional $3 million in one year on the same terms if certain other funding opportunities do not materialize. Additionally, Terren Peizer joined the board of the Company and assume the role of Chairman & Chief Executive Officer, with Jonathan Adams becoming President and Chief Operating Officer.
Mr. Peizer is an entrepreneur, investor, and financier with a particular interest in healthcare, having founded and successfully commercialized several healthcare companies. Mr. Peizer is the founder of Catasys, Inc., a leader in behavioral and mental health management services. He has also served as the Company’s Chairman of the Board of Directors and CEO since the Company’s inception in 2004. Mr. Peizer also is the Founder, Chairman and CEO of NeurMedix, Inc., a biotechnology company with a focus on inflammatory, neurological and neuro-degenerative diseases. NeurMedix’s lead compound NE3107 has shown efficacy in 11 pre-clinical and 6 human studies. These studies resulted in publications in peer-reviewed journals. Mr. Peizer is Chairman of Acuitas Group Holdings, LLC, his personal holding company that is the owner of all of his portfolio company interests, including Catasys, Inc. Through Acuitas, Mr. Peizer also owns Crede Capital Group, LLC, an industry leader in investing in micro and small capitalization equities, having invested over $1.2 billion directly into portfolio companies. Mr. Peizer has been the largest beneficial shareholder, and has held various senior executive positions with several other publicly-traded growth companies, including Chairman of internationally renowned Cray, Inc., the industry’s leading supercomputer company. Mr. Peizer has a background in venture capital, investing, mergers and acquisitions, corporate finance, and previously held senior executive positions with the investment banking firms Goldman Sachs, First Boston, and Drexel Burnham Lambert. He received his B.S.E. in finance from The Wharton School of Finance and Commerce.
Raised in Beachwood, Ohio, a suburb of Cleveland, Peizer has been the largest beneficial stockholder and has held various senior executive positions within several technology and biotech companies. He has assisted companies by assembling management teams, boards of directors and scientific advisory boards, formulating business and financial strategies, and investor relations. Mr. Peizer has a background in venture capital, investing, mergers and acquisitions, corporate finance, and previously held senior executive positions with the investment banking firms Goldman Sachs , First Boston and Drexel Burnham Lambert . Mr. Peizer received his B.S.E. in Finance from The Wharton School of Finance and Commerce.
You can follow more of Terren at his personal site:
http://terrenpeizer.com/
whytestocks
5 years ago
News: $CATS Catasys Schedules 2019 Second Quarter Financial Results Conference Call for August 14, 2019
Catasys, Inc. (NASDAQ: CATS) (“Catasys” or the “Company”), a leading AI and technology-enabled healthcare company, today announced that the Company will be releasing financial results for its second quarter ended June 30, 2019, after the closing of the stock market...
Find out more Catasys Schedules 2019 Second Quarter Financial Results Conference Call for August 14, 2019
whytestocks
5 years ago
News: $CATS Catasys to Present at the B. Riley FBR Institutional Investor Conference on Wednesday, May 22, 2019
Catasys, Inc. (NASDAQ: CATS) (“Catasys” or the “Company”), a leading AI and technology-enabled healthcare company, today announced that Mr. Terren Peizer, the Company’s Chairman and Chief Executive Officer, will present at the B. Riley FBR Institutional Inv...
Got this from https://marketwirenews.com/news-releases/catasys-to-present-at-the-b-riley-fbr-institutional-investor-conference-on-wednesday-may-22-2019-8216610.html
Trend-Setter
5 years ago
BioVie, An Undiscovered Gem by Tailwinds Research Group
People who are good at what they do consistently outperform. This is true of many things like sports, entertainment and business. People like Roger Federer and Steve Jobs have consistently outperformed the competition. It is also true of investing where smart people develop track records over time. It is, generally speaking, very rewarding to follow successful investors, like a Warren Buffet, tracking their investments and participating in them when possible.
Tailwinds has developed our strong track record by finding underfollowed stocks that are off the radar screen of most investors; these are, shall we say, “undiscovered gems”. Our discovery of opportunities is frequently accomplished through sourcing ideas from our investor network. That network includes Terren Peizer.
Terren has developed a long-term track record of success running his Acuitas Group fund. He also is the CEO of Catasys, a company in which he has invested substantial personal funds. Catasys also happens to be our largest investment and a big winner for Tailwinds. Thus, it was certainly noteworthy for us when Terren invested millions of dollars to take majority control of BioVie, Inc. (BIVI).
Terren suggested that Tailwinds take a look at BioVie. After researching them, it has become readily apparent that this company falls into the category of undiscovered gems. Thus, we have established a position in the stock and are initiating coverage on it at Tailwinds.......https://tailwindsresearch.com/2019/04/biovie-an-undiscovered-gem/
Trend-Setter
5 years ago
BioVie (otcqb:BIVI) TERREN PEIZER, CEO,Board Chairman
Mr. Peizer is an entrepreneur and an investor with a particular interest in healthcare, having founded and successfully commercialized several healthcare companies. Mr. Peizer is the founder of Catasys, Inc., a publicly traded leader in behavioral and mental health management services. He has also served as the Company’s Chairman of the Board of Directors and CEO since the Company’s inception in 2004. Catasys has contracted with 7 of the 8 largest health plans in the USA that covers 70% of the country's population. Mr. Peizer also is the Founder, Chairman and CEO of NeurMedix, Inc., a biotechnology company with a focus on inflammatory, neurological and neuro-degenerative diseases. NeurMedix’s lead compound NE3107 has shown efficacy in 11 pre-clinical and 6 human studies. These studies resulted in publications in peer-reviewed journals. Mr. Peizer is also the Chairman, CEO and majority shareholder of publicly traded BioVie, Inc. which is the industry leader in the development of two orphan drug candidates for the treatment of the rare liver diseases Ascites and HRS. Mr. Peizer is Chairman of Acuitas Group Holdings, LLC, his personal holding company that is the owner of all of his portfolio company interests, including Catasys, Inc. Through Acuitas, Mr. Peizer also owns Acuitas Capital Group, LLC, an industry leader in investing in publicly traded micro and small capitalization equities, having invested over $1.5 billion directly into portfolio companies. Mr. Peizer has been the largest beneficial shareholder, and has held various senior executive positions with several other publicly-traded growth companies, including Chairman of internationally renowned Cray, Inc., the industry’s leading supercomputer company. Mr. Peizer has a background in finance and capital markets having previously held senior executive positions with the investment banking firms Goldman Sachs, First Boston, and Drexel Burnham Lambert. He received his B.S.E. in finance from The Wharton School.
Level up your trading with our powerful tools and real-time insights all in one place.
JohnCM
4 years ago
ncj167
4 years ago
stocktrademan
5 years ago
cash_boy
7 years ago
Renee
7 years ago
Hot Features
Premium
